tbuckley/cabot-search huggingface dataset:
Labeling Errors in Flow Diagram
Journal: JAMA Pediatrics (2022)

Nia Goulden, PhD; Michael Cousins, MRCPCH; Kylie Hart, MSc; Alison Jenkins; Gill Willetts, BSc; Louise Yendle, BSc; Iolo Doull, MD; E. Mark Williams, PhD; Zoe Hoare, PhD; Sailesh Kotecha, MD, PhD
Prenatal Antipsychotic Exposure and Performance in Neurodevelopmental Outcomes Among Schoolchildren
Authors: Zhang Jingjing, Wang Li, Yuan Yuan
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Covid-19: What can China learn from Hong Kong and Singapore about exiting zero covid?
Authors: David Owens, Jane Parry
Journal: BMJ (2022)

China's "zero covid" strategy was successful in protecting the Chinese population throughout the first phase of the covid-19 pandemic.However, following widespread recent protests in Beijing, Shanghai, and elsewhere, ostensibly triggered by a fatal fire in Urumqi and aggravated by pictures of maskless fans at the football World Cup, the Chinese government announced that most of its covid restrictions would be relaxed.As Mainland China retreats from its zero covid policies what lessons can China take from the management of covid-19 in Hong Kong and Singapore?
COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia
Authors: Mazyar Shadman, Catherine Liu, Katherine Eakle, Hwai J. Hiew, Juliana M.L. Biondo, Paolo Ghia, Anthony R. Mato
Journal: HemaSphere (2022)

Patients with chronic lymphocyticleukemia (CLL) typically have innate/adaptive immune system dysregulation, thus the protective effect of coronavirus disease 2019 (COVID-19) vaccination remains uncertain. This prospective review evaluates vaccination response in these patients, including seropositivity rates by CLL treatment status, type of treatment received, and timing of vaccination. Antibody persistence, predictors of poor vaccine response, and severity of COVID-19 infection in vaccinated patients were also analyzed. Practical advice on the clinical management of patients with CLL is provided. Articles reporting COVID-19 vaccination in patients with CLL, published January 1, 2021–May 1, 2022, were included. Patients with CLL displayed the lowest vaccination responses among hematologic malignancies; however, seropositivity increased with each vaccination. One of the most commonly reported independent risk factors for poor vaccine response was active CLL treatment; others included hypogammaglobulinemia and age &gt;65–70 years. Patients who were treatment-naive, off therapy, in remission, or who had a prior COVID-19 infection displayed the greatest responses. Further data are needed on breakthrough infection rates and a heterologous booster approach in patients with hematologic malignancies. Although vaccine response was poor for patients on active therapy regardless of treatment type, CLL management in the context of COVID-19 should aim to avoid delays in antileukemic treatment, especially with the advent of numerous strategies to mitigate risk of severe COVID-19 such as pre-exposure prophylaxis, and highly effective antivirals and monoclonal antibody therapy upon confirmed infection. Patients with CLL should remain vigilant in retaining standard prevention measures such as masks, social distancing, and hand hygiene.
Biomaterials‐Based Cell Therapy for Myocardial Tissue Regeneration
Authors: Lei Mu, Ruonan Dong, Baolin Guo
Journal: Advanced Healthcare Materials (2022)

Abstract Cardiovascular diseases (CVDs) have been the leading cause of death worldwide during the past several decades. Cell loss is the main problem that results in cardiac dysfunction and further mortality. Cell therapy aiming to replenish the lost cells is proposed to treat CVDs especially ischemic heart diseases which lead to a big portion of cell loss. Due to the direct injection's low cell retention and survival ratio, cell therapy using biomaterials as cell carriers has attracted more and more attention because of their promotion of cell delivery and maintenance at the aiming sites. In this review, the three main factors involved in cell therapy for myocardial tissue regeneration: cell sources (somatic cells, stem cells, and engineered cells), chemical components of cell carriers (natural materials, synthetic materials, and electroactive materials), and categories of cell delivery materials (patches, microspheres, injectable hydrogels, nanofiber and microneedles, etc.) are systematically summarized. An introduction of the methods including magnetic resonance/radionuclide/photoacoustic and fluorescence imaging for tracking the behavior of transplanted cells in vivo is also included. Current challenges of biomaterials‐based cell therapy and their future directions are provided to give both beginners and professionals a clear view of the development and future trends in this area.
The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell–mediated graft-versus-host disease
Authors: Qiao Cheng, Dong Wang, Xiaoxuan Lai, Yin Liu, Yibo Zuo, Wenli Zhang, Lei Lei, Jia Chen, Hong Liu, Ying Wang, Haiyan Liu, Hui Zheng, Depei Wu, Yang Xu
Journal: Blood (2022)
Nonsteroidal anti-inflammatory drugs as a targeted therapy for bone marrow failure in Ghosal hematodiaphyseal dysplasia
Authors: Timothy J. Brown, Neil Barrett, Hu Meng, Emanuela Ricciotti, Ciara McDonnell, Andrew Dancis, Julianne Qualtieri, Garret A. FitzGerald, Melanie Cotter, Daria V. Babushok
Journal: Blood (2022)
Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy
Authors: Saad N. Mohammad, Yeon Su Choi, Jee Young Chung, Edward Cedrone, Barry W. Neun, Marina A. Dobrovolskaia, Xiaojing Yang, Wei Guo, Yap Ching Chew, Juwan Kim, Seunggul Baek, Ik Soo Kim, David A. Fruman, Young Jik Kwon
Journal: Journal of Controlled Release (2023)
Brain activity measured by functional brain imaging predicts breathlessness improvement during pulmonary rehabilitation
Authors: Sarah L Finnegan, Michael Browning, Eugene Duff, Catherine J Harmer, Andrea Reinecke, Najib M Rahman, Kyle T S Pattinson
Journal: Thorax (2022)

Chronic breathlessness in chronic obstructive pulmonary disease (COPD) is effectively treated with pulmonary rehabilitation. However, baseline patient characteristics predicting improvements in breathlessness are unknown. This knowledge may provide better understanding of the mechanisms engaged in treating breathlessness and help to individualise therapy. Increasing evidence supports the role of expectation (ie, placebo and nocebo effects) in breathlessness perception. In this study, we tested functional brain imaging markers of breathlessness expectation as predictors of therapeutic response to pulmonary rehabilitation, and asked whether D-cycloserine, a brain-active drug known to influence expectation mechanisms, modulated any predictive model.Data from 71 participants with mild-to-moderate COPD recruited to a randomised double-blind controlled experimental medicine study of D-cycloserine given during pulmonary rehabilitation were analysed (ID: NCT01985750). Baseline variables, including brain-activity, self-report questionnaires responses, clinical measures of respiratory function and drug allocation were used to train machine-learning models to predict the outcome, a minimally clinically relevant change in the Dyspnoea-12 score.Only models that included brain imaging markers of breathlessness-expectation successfully predicted improvements in Dyspnoea-12 score (sensitivity 0.88, specificity 0.77). D-cycloserine was independently associated with breathlessness improvement. Models that included only questionnaires and clinical measures did not predict outcome (sensitivity 0.68, specificity 0.2).Brain activity to breathlessness related cues is a strong predictor of clinical improvement in breathlessness over pulmonary rehabilitation. This implies that expectation is key in breathlessness perception. Manipulation of the brain's expectation pathways (either pharmacological or non-pharmacological) therefore merits further testing in the treatment of chronic breathlessness.
Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children
Authors: Svea Stratmann, Mattias Vesterlund, Husen M. Umer, Saeed Eshtad, Aron Skaftason, Morten Krogh Herlin, Christer Sundström, Anna Eriksson, Martin Höglund, Josefine Palle, Jonas Abrahamsson, Kirsi Jahnukainen, Monica Cheng Munthe-Kaas, Bernward Zeller, Katja Pokrovskaja Tamm, Cecilia Lindskog, Lucia Cavelier, Janne Lehtiö, Linda Holmfeldt
Journal: Leukemia (2022)

Abstract Despite improvement of current treatment strategies and novel targeted drugs, relapse and treatment resistance largely determine the outcome for acute myeloid leukemia (AML) patients. To identify the underlying molecular characteristics, numerous studies have been aimed to decipher the genomic- and transcriptomic landscape of AML. Nevertheless, further molecular changes allowing malignant cells to escape treatment remain to be elucidated. Mass spectrometry is a powerful tool enabling detailed insights into proteomic changes that could explain AML relapse and resistance. Here, we investigated AML samples from 47 adult and 22 pediatric patients at serial time-points during disease progression using mass spectrometry-based in-depth proteomics. We show that the proteomic profile at relapse is enriched for mitochondrial ribosomal proteins and subunits of the respiratory chain complex, indicative of reprogrammed energy metabolism from diagnosis to relapse. Further, higher levels of granzymes and lower levels of the anti-inflammatory protein CR1/CD35 suggest an inflammatory signature promoting disease progression. Finally, through a proteogenomic approach, we detected novel peptides, which present a promising repertoire in the search for biomarkers and tumor-specific druggable targets. Altogether, this study highlights the importance of proteomic studies in holistic approaches to improve treatment and survival of AML patients.
Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia
Authors: Namrata Rastogi, Juan Bautista Menendez Gonzalez, Vikas Kumar Srivastava, Bader Alanazi, Rehab N. Alanazi, Owen M. Hughes, Niamh S. O’Neill, Amanda F. Gilkes, Neil Ashley, Sumukh Deshpande, Robert Andrews, Adam Mead, Neil P. Rodrigues, Steve Knapper, Richard L. Darley, Alex Tonks
Journal: Leukemia (2022)

Abstract Nuclear factor I-C (NFIC) belongs to a family of NFI transcription factors that binds to DNA through CAATT-boxes and are involved in cellular differentiation and stem cell maintenance. Here we show NFIC protein is significantly overexpressed in 69% of acute myeloid leukemia patients. Examination of the functional consequences of NFIC overexpression in HSPCs showed that this protein promoted monocytic differentiation. Single-cell RNA sequencing analysis further demonstrated that NFIC overexpressing monocytes had increased expression of growth and survival genes. In contrast, depletion of NFIC through shRNA decreased cell growth, increased cell cycle arrest and apoptosis in AML cell lines and AML patient blasts. Further, in AML cell lines (THP-1), bulk RNA sequencing of NFIC knockdown led to downregulation of genes involved in cell survival and oncogenic signaling pathways including mixed lineage leukemia-1 (MLL-1). Lastly, we show that NFIC knockdown in an ex vivo mouse MLL::AF9 pre-leukemic stem cell model, decreased their growth and colony formation and increased expression of myeloid differentiation markers Gr1 and Mac1. Collectively, our results suggest that NFIC is an important transcription factor in myeloid differentiation as well as AML cell survival and is a potential therapeutic target in AML.
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Authors: Samir K Gupta, Mezgebe Berhe, Gordon Crofoot, Paul Benson, Moti Ramgopal, James Sims, Cheryl McDonald, Peter Ruane, William E Sanchez, Anita Scribner, Shan-Yu Liu, Laurie A VanderVeen, Hadas Dvory-Sobol, Martin S Rhee, Jared M Baeten, Ellen Koenig
Journal: The Lancet HIV (2022)
Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies
Authors: Jean-Baptiste Vulsteke, Rita Derua, Sylvain Dubucquoi, Frédéric Coutant, Sebastien Sanges, David Goncalves, Greet Wuyts, Petra De Haes, Daniel Blockmans, Wim A Wuyts, Kristl G Claeys, Ellen De Langhe, Nicole Fabien, Xavier Bossuyt
Journal: Annals of the Rheumatic Diseases (2022)

To discover new and detect known antisynthetase autoantibodies (ASAs) through protein immunoprecipitation combined with gel-free liquid chromatography-tandem mass spectrometry (IP-MS).IP-MS was performed using sera of individuals showing features of antisynthetase syndrome (ASyS) without (n=5) and with (n=12) previously detected ASAs, and healthy controls (n=4). New candidate aminoacyl-tRNA-synthetase (ARS) autoantigens identified through unbiased IP-MS were confirmed by IP-western blot. A targeted IP-MS assay for various ASA specificities was developed and validated with sera of patients with known ASAs (n=16), disease controls (n=20) and healthy controls (n=25). The targeted IP-MS assay was applied in an additional cohort of patients with multiple ASyS features or isolated myositis without previously detected ASAs (n=26).Autoantibodies to cytoplasmic cysteinyl-tRNA-synthetase (CARS1) were identified by IP-MS and confirmed by western blot as a new ASA specificity, named anti-Ly, in the serum of a patient with ASyS features. Rare ASAs, such as anti-OJ, anti-Zo and anti-KS, and common ASAs could also be identified by IP-MS. A targeted IP-MS approach for ASA detection was developed and validated. Application of this method in an additional cohort identified an additional patient with anti-OJ autoantibodies that were missed by line and dot immunoassays.CARS1 is the dominant cognate ARS autoantigen of the newly discovered anti-Ly ASA specificity. Rare and common ASA specificities could be detected by both unbiased and targeted IP-MS. Unbiased and targeted IP-MS are promising methods for discovery and detection of autoantibodies, especially autoantibodies that target complex autoantigens.
Patterns in Prescription Opioids, Benzodiazepines, and Stimulants Filled by Pregnant Medicaid Beneficiaries
Authors: Angélica Meinhofer, Meralis Lantigua Martinez, Kristin Palmsten
Journal: JAMA Pediatrics (2022)

This study analyzes patterns in prescriptions filled by pregnant Medicaid beneficiaries for opioids, benzodiazepines, and stimulants.
Prenatal Antipsychotic Exposure and Performance in Neurodevelopmental Outcomes Among Schoolchildren—Reply
Authors: Xiaoqin Liu, Betina Bitsch Trabjerg, Julie Werenberg Dreier
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Racial Disparities in School Belonging and Prospective Associations With Diabetes and Metabolic Syndrome
Authors: Edith Chen, Phoebe H. Lam, Tianyi Yu, Gene H. Brody
Journal: JAMA Pediatrics (2022)

School belonging has important implications for academic, psychological, and health outcomes, but the associations between racial disparities in school belonging and health have not been explored to date.To examine associations between school-level racial disparities in belonging and cardiometabolic health into adulthood in a national sample of Black and White children, adolescents, and young adults.Prospective cohort study of a US national sample of 4830 Black and White students (National Longitudinal Study of Adolescent Health) followed up for 13 years. The study was conducted from 1994 to 1995 for wave 1 and in 2008 for wave 4. Data were analyzed from June 14 to August 13, 2021.School-level racial disparities in belonging at baseline were calculated as the mean level of school belonging for Black students minus the mean level of school belonging for White students at the school that they attended when they were aged 12 to 20 years. Diabetes and metabolic syndrome were measured as outcomes for these same participants at 24 to 32 years of age.The study included 4830 students. For wave 1, mean (SD) age was 16.1 (1.7) years, and for wave 4, 29.0 (1.7) years. A total of 2614 (54.1%) were female, 2219 were non-Hispanic Black (45.9%), and 2611 were non-Hispanic White (54.1%). Among Black students, attending a school with a greater Black-White disparity in school belonging (more negative scores) was associated with an increased risk for diabetes (odds ratio, 0.66 [95% CI, 0.46-0.95]) and more risk factors for metabolic syndrome (rate ratio, 0.95 [95% CI, 0.90-1.00]) in adulthood 13 years later. These associations persisted above individual-level controls (age, sex, and body mass index) and school-level controls (school size, percentage of Black students, and percentage of Black teachers) and were not explained by either an individual's own perception of school belonging or the mean level of belonging across the whole school.In this prospective cohort study of US students, racial disparities in school belonging were associated with risks for diabetes and metabolic syndrome in Black students. Among students, fostering a more equal sense of school belonging across racial groups may have implications for health disparities in the cardiometabolic domain into adulthood.
Author Correction: The persistence of memory: defining, engineering, and measuring vaccine durability
Authors: Amy C. Palin, Galit Alter, Shane Crotty, Ali H. Ellebedy, M. Chelsea Lane, F. Eun-Hyung Lee, Michela Locci, Angela Malaspina, Conrad Mallia, M. Juliana McElrath, Bali Pulendran, Anjali Singh, M. Patricia D’Souza
Journal: Nature Immunology (2022)
A promising future for hypothalamic dysfunction in craniopharyngioma
Authors: John Richard Apps, Juan Pedro Martinez-Barbera
Journal: Neuro-Oncology (2022)

Journal Article A promising future for hypothalamic dysfunction in craniopharyngioma Get access John Richard Apps, John Richard Apps Institute of Cancer and Genomics Sciences, University of Birmingham, Edgbaston Campus, Birmingham, B15 2TT, UKDevelopmental Biology and Cancer, Birth Defects Research Centre, GOS Institute of Child Health, University College London, WC1N 1EH, London, UKBirmingham Women's and Children's NHS Foundation Trust, Birmingham, UK Search for other works by this author on: Oxford Academic PubMed Google Scholar Juan Pedro Martinez-Barbera Juan Pedro Martinez-Barbera Developmental Biology and Cancer, Birth Defects Research Centre, GOS Institute of Child Health, University College London, WC1N 1EH, London, UK Corresponding Author: Juan Pedro Martinez-Barbera, PhD, University College London, London, UK (j.martinez-barbera@ucl.ac.uk). https://orcid.org/0000-0002-5292-7276 Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, Volume 25, Issue 4, April 2023, Pages 733–734, https://doi.org/10.1093/neuonc/noac284 Published: 27 December 2022 Article history Published: 27 December 2022 Corrected and typeset: 13 January 2023
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
Authors: Adrián Mosquera-Orgueira, Manuel Pérez-Encinas, Alberto Hernández-Sánchez, Teresa González-Martínez, Eduardo Arellano-Rodrigo, Javier Martínez-Elicegui, Ángela Villaverde-Ramiro, José-María Raya, Rosa Ayala, Francisca Ferrer-Marín, María-Laura Fox, Patricia Velez, Elvira Mora, Blanca Xicoy, María-Isabel Mata-Vázquez, María García-Fortes, Anna Angona, Beatriz Cuevas, María-Alicia Senín, Angel Ramírez-Payer, María-José Ramírez, Raúl Pérez-López, Sonia González de Villambrosía, Clara Martínez-Valverde, María-Teresa Gómez-Casares, Carmen García-Hernández, Mercedes Gasior, Beatriz Bellosillo, Juan-Luis Steegmann, Alberto Álvarez-Larrán, Jesús María Hernández-Rivas, Juan Carlos Hernández-Boluda
Journal: HemaSphere (2022)

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Therefore, accurate disease risk prognostication is critical for treatment decision-making. We obtained registry data from patients diagnosed with MF in 60 Spanish institutions (N = 1386). These were randomly divided into a training set (80%) and a test set (20%). A machine learning (ML) technique (random forest) was used to model overall survival (OS) and leukemia-free survival (LFS) in the training set, and the results were validated in the test set. We derived the AIPSS-MF (Artificial Intelligence Prognostic Scoring System for Myelofibrosis) model, which was based on 8 clinical variables at diagnosis and achieved high accuracy in predicting OS (training set c-index, 0.750; test set c-index, 0.744) and LFS (training set c-index, 0.697; test set c-index, 0.703). No improvement was obtained with the inclusion of MPN driver mutations in the model. We were unable to adequately assess the potential benefit of including adverse cytogenetics or high-risk mutations due to the lack of these data in many patients. AIPSS-MF was superior to the IPSS regardless of MF subtype and age range and outperformed the MYSEC-PM in patients with secondary MF. In conclusion, we have developed a prediction model based exclusively on clinical variables that provides individualized prognostic estimates in patients with primary and secondary MF. The use of AIPSS-MF in combination with predictive models that incorporate genetic information may improve disease risk stratification.